Johnson & Johnson surprised the markets with its Q4 2020 figures
Johnson&
Johnson reported an EPS of $1.86, which was higher than what the market
expected - $1.82 per share. Also, the revenues topped the $21.67 billion
forecasted, coming in at $22.48 billion.
The most significant increase was reported by the
pharmaceutical business - $12.26 billion in revenues, largely due to JNJ upcoming
COVID-19 vaccine.
For the future, the company expects its EPS to reach a high
of $9.60 on sales of $91.7 billion. Its data regarding the Phase III COVID-19
vaccine trial is expected by experts as early as next week.
After the news hit the wires, JNJ stock price added 2%.
Source: reuters.com
This information prepared by ClickTrades.com is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.
This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient.
You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.
This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of ClickTrades.com.
Previous Article
Giuseppe Conte forced to leave office amid pandemic criticism
Next Article
Mixed bag for Boeing
